Psoriasis: risankizumab shows good long-term efficacy in phase 3 RCT

  • Blauvelt A & al.
  • JAMA Dermatol
  • 08/04/2020

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Risankizumab was associated with improved efficacy compared with placebo at 16 weeks in this phase 3 randomized controlled trial (RCT).
  • It also is associated with improved efficacy compared with treatment withdrawal at 1 and 2 years for patients with moderate to severe plaque psoriasis.

Why this matters

  • Risankizumab appears to represent a promising method for maintaining clinical efficacy in these patients.

Key results

  • At week 16, vs placebo, risankizumab was associated with higher rates of:
    • ≥90% improvement in the Psoriasis Area and Severity Index: 73.2% vs 2.0% (P<.001>
    • Static Physician’s Global Assessment (sPGA) score 0/1: 83.5% vs 7.0% (P<.001>
  • Compared with treatment withdrawal, risankizumab was associated with higher rates sPGA score 0/1 at:
    • 1 year: 87.4% vs 61.3%.
    • 2 years: 81.1% vs 7.1% (P<.001 for both>
  • Risankizumab and placebo were associated with similar rates of treatment-emergent adverse events at week 16 (45.7% vs 49.0%).

Study design

  • 507 patients with moderate to severe plaque psoriasis were randomly assigned to risankizumab (n=407) or placebo (n=100).
  • At week 28, a total of 336 responders were randomly allocated to risankizumab (n=111) or treatment withdrawal (n=225).
  • Funding: AbbVie, Boehringer Ingelheim.

Limitations

  • Lack of QoL measurements.